# Martin Windpessl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/martin-windpessl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 977 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 17 |
| i10-index | 23 |
| Last Known Institution | Klinikum Wels-Grieskirchen |
| OpenAlex ID | https://openalex.org/A5060617276 |
| ORCID iD | 0000-0002-6273-7513 |
| Works | 85 |

## Researcher papers

- [COVID-19 vaccines and kidney disease](https://scholariq.org/papers/covid-19-vaccines-and-kidney-disease/)
- [COVID-19: implications for immunosuppression in kidney disease and transplantation](https://scholariq.org/papers/covid-19-implications-for-immunosuppression-in-kidney-disease-and/)
- [Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?](https://scholariq.org/papers/rituximab-in-adult-minimal-change-disease-and-focal-segmental-glomerulosclerosis/)
- [Chronic kidney disease is more prevalent among women but more men than women are under nephrological care](https://scholariq.org/papers/chronic-kidney-disease-is-more-prevalent-among-women-but-more-men-than-women-are/)
- [Rituximab for immunologic renal disease: What the nephrologist needs to know](https://scholariq.org/papers/rituximab-for-immunologic-renal-disease-what-the-nephrologist-needs-to-know/)
- [A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health](https://scholariq.org/papers/a-randomized-controlled-trial-of-alanyl-glutamine-supplementation-in-peritoneal/)
- [“Bowel prep hyponatremia“ – a state of acute water intoxication facilitated by low dietary solute intake: case report and literature review](https://scholariq.org/papers/bowel-prep-hyponatremia-a-state-of-acute-water-intoxication-facilitated-by-low/)
- [A Novel Homozygous <b><i>SLC2A9</i></b> Mutation Associated with Renal-Induced Hypouricemia](https://scholariq.org/papers/a-novel-homozygous-and-lt-b-and-gt-and-lt-i-and-gt-slc2a9-and-lt-i-and-gt-and-lt/)
- [The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab](https://scholariq.org/papers/the-first-case-of-a-patient-with-neutropenia-and-giant-cell-arteritis-treated/)
- [Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies](https://scholariq.org/papers/long-term-outcomes-of-rituximab-treated-adult-patients-with-podocytopathies/)
- [Rituximab in glomerular diseases: Indications, long-term use, complications and research gaps](https://scholariq.org/papers/rituximab-in-glomerular-diseases-indications-long-term-use-complications-and/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Electrolyte and hormonal disorders](https://scholariq.org/topics/electrolyte-and-hormonal-disorders/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)

## Researcher university

- [Klinikum Wels-Grieskirchen](https://scholariq.org/institutions/klinikum-wels-grieskirchen/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.